Holen Sie sich die Stockscreener-App
203.50
0.40%
-0.81
Handel nachbörslich:
203.96
0.46
+0.23%
Schlusskurs vom Vortag:
$204.31
Offen:
$204.21
24-Stunden-Volumen:
1.21M
Relative Volume:
1.22
Marktkapitalisierung:
$14.33B
Einnahmen:
$2.71B
Nettoeinkommen (Verlust:
$247.10M
KGV:
58.13
EPS:
3.5008
Netto-Cashflow:
$349.90M
1W Leistung:
-2.17%
1M Leistung:
-14.14%
6M Leistung:
-34.71%
1J Leistung:
-17.03%
1-Tages-Spanne:
$202.75
$206.32
1-Wochen-Bereich:
$202.44
$212.92
52-Wochen-Spanne:
$202.44
$354.88
Insulet Corporation Stock (PODD) Company Profile
Firmenname
Insulet Corporation
Sektor
Branche
Telefon
978-600-7000
Adresse
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
203.50 | 14.38B | 2.71B | 247.10M | 349.90M | 3.5008 |
ABT
Abbott Laboratories
|
102.30 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
332.30 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.28 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.59 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.19 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Fortgesetzt | TD Cowen | Hold |
| 2026-01-12 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-16 | Eingeleitet | Evercore ISI | Outperform |
| 2025-11-19 | Hochstufung | UBS | Neutral → Buy |
| 2025-10-21 | Fortgesetzt | Stifel | Buy |
| 2025-09-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-05-13 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-06 | Eingeleitet | Bernstein | Outperform |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-05-07 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | Hochstufung | Jefferies | Hold → Buy |
| 2023-08-21 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-08-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-01-26 | Eingeleitet | Wolfe Research | Peer Perform |
| 2022-11-04 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-07-28 | Eingeleitet | Wells Fargo | Overweight |
| 2020-04-24 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-03-31 | Herabstufung | Berenberg | Buy → Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-10 | Eingeleitet | CFRA | Sell |
| 2019-10-23 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-10-04 | Herabstufung | UBS | Buy → Neutral |
| 2019-10-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-06-10 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | Hochstufung | BTIG Research | Neutral → Buy |
| 2018-04-20 | Eingeleitet | Berenberg | Buy |
| 2018-02-22 | Bestätigt | Barclays | Overweight |
| 2018-01-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Insulet Corporation Aktie (PODD) Neueste Nachrichten
Insulet announces recall of Omnipod 5 Pods due to insulin delivery issue - Class Action Lawsuits
Insulet Corp. Stock Plummets to New 52-Week Low of $203.19 - Markets Mojo
Insulet Corporation (PODD) Stock forecasts - Yahoo Finance UK
Aberdeen Group plc Has $64.08 Million Stock Position in Insulet Corporation $PODD - MarketBeat
PODD PE Ratio & Valuation, Is PODD Overvalued - Intellectia AI
Insulet (PODD): 3 Reasons We Love This Stock - Yahoo Finance
Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
Insulet Corp. Stock Hits 52-Week Low at USD 208.14 - Markets Mojo
Assessing Insulet (PODD) Valuation After Omnipod 5 Device Correction And Maintained Outlook - Sahm
Insulet Corp. stock outperforms competitors despite losses on the day - MarketWatch
Insulet Corp (PODD) EVP receives new stock options and RSU awards - Stock Titan
INSULET CORP (PODD) EVP and CCO Michael Panos reports 5-share stake - Stock Titan
Insulet (PODD) board member elects 111 deferred stock units as fees - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet CorporationPODD - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Insulet Corporation (PODD) And Encourages Shareholders to Connect - ACCESS Newswire
Insulet Corp (NASDAQ:PODD): A Prime GARP Investment with Strong Growth and Reasonable Valuation - ChartMill
Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026 - BioSpace
PODD Stock Price, Quote & Chart | INSULET CORP (NASDAQ:PODD) - ChartMill
Diabetes Focused MiniMed Recovery Story Builds As Pipeline Improves - Sahm
Insulet Corp (1PODD.MI) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Insulet Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Insulet Corporation (PODD) Stock Forecasts - Yahoo Finance
Insulet Corporation Trade Ideas — MIL:1PODD - TradingView
PODD Investor Alert: Insulet Corp. Potential Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Device Defect: Levi & Korsinsky - Morningstar
Does Insulet (PODD) Elevate Its Diabetes Tech Edge With Panos Steering Global Commercial Strategy? - Yahoo Finance
7,473 Shares in Insulet Corporation $PODD Acquired by J. Safra Sarasin Holding AG - MarketBeat
Truist maintains Insulet Corporation (PODD) buy rating despite device correction announcement - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Insulet Corporation (PODD) And Encourages Shareholders to Reach Out - ACCESS Newswire
Why (PODD) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet ... - Bluefield Daily Telegraph
Winners And Losers Of Q4: Insulet (NASDAQ:PODD) Vs The Rest Of The Patient Monitoring Stocks - Yahoo Finance
Zevenbergen Capital Investments LLC Invests $32.14 Million in Insulet Corporation $PODD - MarketBeat
Insulet (NASDAQ:PODD) Reaches New 12-Month LowTime to Sell? - MarketBeat
Insulet names Mike Panos as chief commercial officer By Investing.com - Investing.com South Africa
Insulet Appoints Mike Panos as Chief Commercial Officer - gurufocus.com
Insulet Earnings: Stellar Finish to 2025 With Strong Fourth Quarter - Morningstar
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insulet Corporation (PODD) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Insulet Corp. Stock Hits New 52-Week Low at USD 215.26 - Markets Mojo
Consumer safety roundup: Major recalls affect Einstein Bros., Insulet, Amneal and Falcon Trading - Washington Times
Insulet Corp (PODD) Shares Down 4.53% on Mar 30 - gurufocus.com
Is Insulet’s (PODD) New CCO Hire a Subtle Reset of Its Global Commercial Strategy? - simplywall.st
Insulet Corporation Appoints Mike Panos as Executive Vice President and Chief Commercial Officer, Effective March 30, 2026 - marketscreener.com
Insulet names Mike Panos as chief commercial officer - Investing.com
Truist Maintains Insulet Corporation (PODD) Buy Rating Despite Device Correction Announcement - Insider Monkey
SG Americas Securities LLC Purchases 36,570 Shares of Insulet Corporation $PODD - MarketBeat
Beacon Investment Advisory Services Inc. Cuts Position in Insulet Corporation $PODD - MarketBeat
Insulet Corporation (PODD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Insulet recalling certain defective Omnipod insulin delivery devices - MSN
PODD Investors Have Opportunity to Join Insulet Corporation Fraud Investigation with the Schall Law Firm - Business Wire
Is Insulet stock underperforming the Dow? - MSN
Insulet Corp. stock underperforms Friday when compared to competitors - MarketWatch
Finanzdaten der Insulet Corporation-Aktie (PODD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Insulet Corporation-Aktie (PODD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McEvoy Ashley | President and CEO |
Feb 20 '26 |
Buy |
239.35 |
4,300 |
1,029,205 |
13,916 |
| Frederick Wayne A.I. | Director |
Dec 15 '25 |
Sale |
293.09 |
1,851 |
542,510 |
2,158 |
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):